LR 19051
Alternative Names: LR-19051Latest Information Update: 28 Jul 2022
At a glance
- Originator LG Chem
- Class Antihyperglycaemics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase I Type 2 diabetes mellitus
Most Recent Events
- 28 Jul 2022 LR 19051 is available for licensing as of 28 Jul 2022. https://innovation.lgchem.com/ResearchDevelopment/Partnership.do
- 21 Jul 2022 Phase-I clinical trials in Type 2 diabetes mellitus (Combination therapy) in South Korea (unspecified route) Prior to July 2022